Daiwa Securities Group Inc. Has $1.33 Million Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Daiwa Securities Group Inc. decreased its stake in Catalent, Inc. (NYSE:CTLT) by 4.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,011 shares of the company’s stock after selling 925 shares during the period. Daiwa Securities Group Inc.’s holdings in Catalent were worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in CTLT. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after acquiring an additional 14,373 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Catalent by 289.8% in the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock valued at $2,986,000 after purchasing an additional 36,652 shares in the last quarter. Swedbank AB bought a new stake in Catalent during the first quarter worth $1,659,000. New York Life Investment Management LLC lifted its holdings in Catalent by 67.9% during the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock worth $16,751,000 after acquiring an additional 120,502 shares during the period. Finally, Natixis Advisors LLC bought a new stake in Catalent during the third quarter worth $1,287,000.

Insiders Place Their Bets

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is currently owned by company insiders.

Catalent Trading Up 0.2 %

Shares of CTLT stock opened at $61.12 on Friday. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business has a 50-day moving average of $59.90 and a 200 day moving average of $58.47. The stock has a market capitalization of $11.09 billion, a PE ratio of -27.04, a P/E/G ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the business posted ($0.10) EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on CTLT. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, Catalent has a consensus rating of “Hold” and a consensus target price of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.